Revolutionizing Precision Heart Care
HeartFlow brings together human ingenuity and advanced technology to help combat heart disease, the leading cause of death.

HeartFlow's non-invasive, personalized cardiac test provides unprecedented visualization of each patient’s coronary arteries, enabling physicians to create more effective treatment plans for their patients.
Superior Quality

By combining review from trained analysts, who have over 500,000 hours of collective experience, with AI-powered algorithms trained on millions of CT images, HeartFlow is bringing a new level of precision to non-invasive detection of heart disease.

» 2x more likely to identify disease than other tests¹

» Low false negative and false positive rates reported in real-world clinical use²

» “Core Lab” quality control monitoring program with over 10,000 measurements²
Since inception, HeartFlow has been committed to producing comprehensive clinical evidence supporting the diagnostic accuracy, safety, efficacy, cost-effectiveness, and utility of its product portfolio.

With more than 425 publications in prominent peer-reviewed medical journals including JAMA, JACC, Circulation, the American Journal of Cardiology, and Heart, the HeartFlow technology has been proven across diverse patient populations. These clinical activities have included a series of large, multi-center global trials.

ROBUST EVIDENCE

» 16 company-sponsored clinical trials and registries addressing accuracy and outcomes
» 100+ investigator-initiated studies
» 425+ peer-reviewed publications
» Demonstrated safety with long-term data out to 5 years
» Studied in > 10,000 patients
Exceptional Clinical Results

Time and time again, HeartFlow demonstrates unmatched non-invasive diagnostic performance and accuracy, alongside cost-effectiveness and efficacy.

- **83% of avoidable coronary angiograms cancelled**⁴
- **40% reduction in layered testing**⁵
- **Higher diagnostic accuracy** than other common non-invasive cardiac tests³
- **36% improvement in revascularization efficiency**⁵
- **Dominates** stress testing and CTA alone in cost-effectiveness analysis, better outcomes at lower costs⁶
- **$2.7B annual cost savings** delivered to CMS through reduction of invasive diagnostic procedures⁴
Areas of Research

HeartFlow is committed to ongoing research and is interested in exploring the use of $\text{FFR}_{\text{CT}}$ in these populations:

**Coronary Applications**
- Pre-TAVR
- Acute Coronary Syndrome (ACS) - NSTEMI
- Heart Transplant
- Emergency Department
- Perioperative Cardiac Evaluation
- Preventative Screening
- Pediatrics

**Other Applications**
- Neurovascular
- Renovascular
- PAD
Best-in-class Technology

- Patient-specific Interactive 3D Model
- Best-in-class medical image analysis
- Advanced deep learning (AI) methodology to precisely extract coronary anatomy
- AI trained on millions of CT images carefully annotated by expert analysts
- Physics-based computational models assess pressure and flow changes in coronary arteries
- HIPAA and SOC 2 Type II compliant, HITRUST certified
- Secure cloud infrastructure, including encrypted transmission of image data and protected health information (PHI)
- Comprehensive IP portfolio of > 400 issued and allowed patents worldwide, covering innovations in cardiovascular medicine, physiology and bioengineering
As CAD diagnosis increasingly moves to a CTA-led pathway, HeartFlow is developing a comprehensive, integrated solution to help physicians deliver precise, personalized diagnoses and optimize treatment for their patients.

Unparalleled Innovation

Anatomic Stenosis*  |  Physiology & Myocardial Blood Flow^  |  Plaque*  |  Intervention Planning

* Currently in development and not available for clinical use.  ^ Images not representative of actual product.
Outstanding Customer Experience

**FAST**
<4 hour* turnaround time²

**SEAMLESS**
IT integrations streamline workflows

**SECURE**
Ongoing security and software updates

**ECONOMICAL**
No inventory or capital purchase

**EDUCATION**
CTA program and image quality training resources

**SUPPORT**
Dedicated team to facilitate optimized reimbursement

*Median turnaround time. March 2021
About HeartFlow

- Secured regulatory clearance to commercialize first-of-kind, AI-enabled, non-invasive diagnostic simulation of FFR$_{CT}$ (2011: CE Mark, 2014: US FDA De Novo Clearance, 2016: Japan PMDA approval)
- Established Medicare New Technology Ambulatory Payment Classification to reimburse hospitals, effective Jan 1, 2018

- 96% of people in the US have insurance coverage for HeartFlow
- 100,000+ patients have received a HeartFlow Analysis
- Adopted by more than 400 hospitals worldwide, including 80% of the top 50 heart hospitals in the US
REFERENCES


